Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06760507 · ClinicalTrials.gov registry record · NA
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
A NA study of Breast Cancer and Ovarian Cancer, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 3,209
- Enrollment target
- 1
- Study location
NCT06760507 is a NA study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by Emory University. The registered enrollment target is 3,209 participants, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (15% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06760507, a NA study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,209 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial adapts and evaluates the effectiveness of a family history screening program (GA CORE) for increasing uptake of genetic screening for BRCA-associated cancers in women who have received care in rural public health clinics in Southwest Georgia. Brief and low-cost family history-based screening assessments to identify families at high risk for BRCA-associated cancers have been endorsed by national guidelines and public health organizations. Georgia is among the few states to have implemented statewide family history screening for BRCA-associated cancers. Despite its potential, current clinic-based approaches that identify at-risk women are not sustainable and show limited reach. Additionally, uptake of follow-up cancer screening is sub-optimal and solely focuses on women screened as high genetic risk. This trial will adapt the existing family history screening program and then evaluate it's effectiveness for increasing the number and diversity of women who receive a history assessment and subsequent access to risk-based services such as genetic counseling and testing.
Conditions Studied
Interventions
- OTHER Adapted Family History Screening Program
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,209 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06760507
The ClinicalTrials.gov registry entry for NCT06760507 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 3,209 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (15% higher). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Adapted Family History Screening Program is the first listed.
NCT06760507 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06760507 about?
NCT06760507 is a clinical study titled "Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics". This clinical trial adapts and evaluates the effectiveness of a family history screening program (GA CORE) for increasing uptake of genetic screening for BRCA-associated cancers in women who have received care in rural public health clinics in Southwest Georgia. Brief and low-cost family history-bas...
What is the current status of trial NCT06760507?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,209 participants. The study started on 2025-02-01. Estimated completion is 2028-06-30.
What conditions does trial NCT06760507 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT06760507?
The interventions under investigation include: Adapted Family History Screening Program (OTHER).
Who is sponsoring clinical trial NCT06760507?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06760507 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.